Free Trial
→ One executive order. The biggest wealth transfer of your lifetime. (From Reagan Gold Group) (Ad)tc pixel Free KLRS Stock Alerts

Kalaris Therapeutics (KLRS) Stock Forecast & Price Target

Kalaris Therapeutics logo
$5.08 -0.07 (-1.36%)
Closing price 04:00 PM Eastern
Extended Trading
$5.05 -0.03 (-0.59%)
As of 04:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Kalaris Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy
Based on 7 Analyst Ratings
Sell
1
Hold
1
Buy
5

Based on 7 Wall Street analysts who have issued ratings for Kalaris Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 7 analysts, 1 has given a sell rating, 1 has given a hold rating, 4 have given a buy rating, and 1 has given a strong buy rating for KLRS.

Consensus Price Target

$14.00
175.59% Upside
According to the 7 analysts' twelve-month price targets for Kalaris Therapeutics, the average price target is $14.00. The highest price target for KLRS is $20.00, while the lowest price target for KLRS is $3.00. The average price target represents a forecasted upside of 175.59% from the current price of $5.08.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for KLRS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Kalaris Therapeutics and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

KLRS Analyst Ratings Over Time

TypeCurrent Forecast
5/8/25 to 5/8/26		1 Month Ago
4/8/25 to 4/8/26		3 Months Ago
2/7/25 to 2/7/26		1 Year Ago
5/8/24 to 5/8/25
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
 N/A
Buy
4 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
 N/A
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
 N/A
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
 N/A
Consensus Price Target$14.00$14.00$14.00N/A
Forecasted Upside175.59% Upside120.82% Upside67.87% UpsideN/A
Consensus RatingModerate BuyModerate BuyModerate BuyN/A

KLRS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

KLRS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Kalaris Therapeutics Stock vs. The Competition

TypeKalaris TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.71
2.30
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside176.30% Upside853.99% Upside15.17% Upside
News Sentiment Rating
Very Positive News

See Recent KLRS News
Neutral News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
4/16/2026
Morgan Stanley logo
Morgan Stanley
3 of 5 stars
Judah Frommer
Judah Frommer
Not Rated
Initiated CoverageOverweight$14.00+138.50%
12/29/2025
Weiss Ratings logo
Weiss Ratings
Not Rated
 Reiterated RatingSell (D-)
12/23/2025
Chardan Capital logo
Chardan Capital
2 of 5 stars
Daniil Gataulin
Daniil Gataulin
5 of 5 stars
Initiated CoverageBuy$19.00+88.87%
12/18/2025
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOutperform
11/3/2025
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Jonathan Wolleben
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Initiated CoverageMarket Outperform$20.00+297.61%
9/2/2025
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Chris Raymond
Chris Raymond
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Initiated CoverageStrong-Buy
7/23/2025
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Biren Amin
Biren Amin
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Set TargetNeutral$3.00+16.73%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:30 AM ET.


KLRS Forecast - Frequently Asked Questions

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Kalaris Therapeutics is $14.00, with a high forecast of $20.00 and a low forecast of $3.00.

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kalaris Therapeutics in the last year. There is currently 1 sell rating, 1 hold rating, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" KLRS shares.

According to analysts, Kalaris Therapeutics's stock has a predicted upside of 175.59% based on their 12-month stock forecasts.

Kalaris Therapeutics has been rated by research analysts at Morgan Stanley in the past 90 days.

Analysts like Kalaris Therapeutics more than other "medical" companies. The consensus rating for Kalaris Therapeutics is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how KLRS compares to other companies.

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Kalaris Therapeutics Recommendations


This page (NASDAQ:KLRS) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Collect $1,170 a month from silver
I've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...
Investors Alley | Sponsoredtc pixel
Batten down the hatches – Project Tengu is coming
Starting June 16, This AI Lab Could Take Off Dramatically Time magazine recently named this lab "the most d...
Chaikin Analytics | Sponsoredtc pixel
Nobody's Asking Where The SpaceX Money Comes From
When SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...
Americas Gold Company | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel